Montelukast treatment response according to eosinophil-derived neurotoxin level in children with allergic rhinitis
Issued Date
2024-01-01
Resource Type
ISSN
02770903
eISSN
15324303
Scopus ID
2-s2.0-85197446869
Pubmed ID
38884630
Journal Title
Journal of Asthma
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Asthma (2024)
Suggested Citation
Lee Y.J., Ma H.S., Callaway Z., Kim C.K. Montelukast treatment response according to eosinophil-derived neurotoxin level in children with allergic rhinitis. Journal of Asthma (2024). doi:10.1080/02770903.2024.2370002 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/99644
Title
Montelukast treatment response according to eosinophil-derived neurotoxin level in children with allergic rhinitis
Author(s)
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
Background: Eosinophil-derived neurotoxin (EDN) is an important biomarker of eosinophilic inflammation. Methods: This study evaluated Montelukast treatment response according to EDN concentration in children with perennial allergic rhinitis (PAR). Fifty-two children with PAR were recruited and took a combination of Montelukast (5mg) and Levocetirizine (5mg) “Mont/Levo Group” or only Montelukast (5mg) “Mont Group” for 4 weeks. All caregivers were instructed to record rhinitis symptoms for 4 weeks. EDN was measured before and after treatment. Results: Daytime nasal symptom scores (DNSS) significantly decreased in both the Mont/Levo (p = 0.0001; n = 20) and Mont Group (p < 0.0001; n = 20), but there were no significant differences between the two groups. EDN concentration also significantly decreased after treatment in both groups (p < 0.0001 and p < 0.001, respectively). For secondary analysis, children with a high initial EDN concentration (EDN ≥ 53 ng/mL) were placed in the “High EDN Group”, while those with a lower initial EDN concentration (EDN < 53 ng/mL) were put in the “Low EDN Group”. Both groups experienced significant reductions in DNSS after either treatment regimen (p < 0.0001 and p = 0.0027, respectively) but the High EDN Group had greater reductions. EDN concentrations in the High EDN Group decreased significantly from either treatment (p < 0.0001). Conclusion: We found that children with AR and a high serum EDN concentration may respond well to Montelukast treatment. A therapeutic strategy using EDN concentrations in patients with AR to evaluate therapeutic response may help improve quality of care.